|
1
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scaldaferri F and Fiocchi C: Inflammatory
bowel disease: progress and current concepts of etiopathogenesis. J
Dig Dis. 8:171–178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sartor RB: Mechanisms of disease:
pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin
Pract Gastroenterol Hepatol. 3:390–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raza A, Yousaf W, Giannella R and Shata
MT: Th17 cells: interactions with predisposing factors in the
immunopathogenesis of inflammatory bowel disease. Expert Rev Clin
Immunol. 8:161–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cassinotti A, Sarzi-Puttini P, Fichera M,
Shoenfeld Y, de Franchis R and Ardizzone S: Immunity, autoimmunity
and inflammatory bowel disease. Autoimmun Rev. 13:1–2. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geremia A, Biancheri P, Allan P, Corazza
GR and Di Sabatino A: Innate and adaptive immunity in inflammatory
bowel disease. Autoimmun Rev. 13:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kleiner G, Marcuzzi A, Zanin V, Monasta L
and Zauli G: Cytokine levels in the serum of healthy subjects.
Mediators Inflamm. 2013:4340102013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spray C, Debelle GD and Murphy MS: Current
diagnosis, management and morbidity in paediatric inflammatory
bowel disease. Acta Paediatr. 90:400–405. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heikenen JB, Werlin SL, Brown CW and
Balint JP: Presenting symptoms and diagnostic lag in children with
inflammatory bowel disease. Inflamm Bowel Dis. 5:158–160. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis JD: The utility of biomarkers in the
diagnosis and therapy of inflammatory bowel disease.
Gastroenterology. 140:1817–1826. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volpato S, Ferrucci L, Secchiero P, et al:
Association of tumor necrosis factor-related apoptosis-inducing
ligand with total and cardiovascular mortality in older adults.
Atherosclerosis. 215:452–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tisato V, Zauli G, Voltan R, et al:
Endothelial cells obtained from patients affected by chronic venous
disease exhibit a pro-inflammatory phenotype. PLoS One.
7:e395432012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tisato V, Zamboni P, Menegatti E, et al:
Endothelial PDGF-BB produced ex vivo correlates with relevant
hemodynamic parameters in patients affected by chronic venous
disease. Cytokine. 63:92–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neurath MF: Cytokines in inflammatory
bowel disease. Nat Rev Immunol. 14:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Francescone R, Hou V and Grivennikov SI:
Cytokines, IBD, and Colitis-associated Cancer. Inflamm Bowel Dis.
21:409–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wallace KL, Zheng LB, Kanazawa Y and Shih
DQ: Immunopathology of inflammatory bowel disease. World J
Gastroenterol. 20:6–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang W, Su J, Zhang X, Cheng X, Zhou J,
Shi R and Zhang H: Elevated levels of Th17 cells and Th17-related
cytokines are associated with disease activity in patients with
inflammatory bowel disease. Inflamm Res. 63:943–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dinarello CA: Interleukin-1beta and the
autoinflammatory diseases. N Engl J Med. 360:2467–2470. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seegert D, Rosenstiel P, Pfahler H,
Pfefferkorn P, Nikolaus S and Schreiber S: Increased expression of
IL-16 in inflammatory bowel disease. Gut. 48:326–332. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marion R, Coëffier MM, Gargala G, Ducrotté
P and Déchelotte PP: Glutamine and CXC chemokines IL-8, Mig, IP-10
and I-TAC in human intestinal epithelial cells. Clin Nutr.
23:579–585. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Damen GM, Hol J, de Ruiter L, et al:
Chemokine production by buccal epithelium as a distinctive feature
of pediatric Crohn disease. J Pediatr Gastroenterol Nutr.
42:142–149. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mayer L, Sandborn WJ, Stepanov Y, et al:
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II
randomised study. Gut. 63:442–450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Del Zotto B, Mumolo G, Pronio AM,
Montesani C, Tersigni R and Boirivant M: TGF-beta1 production in
inflammatory bowel disease: differing production patterns in
Crohn's disease and ulcerative colitis. Clin Exp Immunol.
134:120–126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe M, Ueno Y, Yajima T, et al:
Interleukin 7 is produced by human intestinal epithelial cells and
regulates the proliferation of intestinal mucosal lymphocytes. J
Clin Invest. 95:2945–2953. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seow CH, Benchimol EI, Griffiths AM and
Steinhart AH: Type I interferons for induction of remission in
ulcerative colitis. Cochrane Database Syst Rev.
3:CD0067902008.PubMed/NCBI
|
|
26
|
Mazzucchelli L, Hauser C, Zgraggen K, et
al: Differential in situ expression of the genes encoding the
chemokines MCP-1 and RANTES in human inflammatory bowel disease. J
Pathol. 178:201–206. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimm MC and Doe WF: Chemokines in
inflammatory bowel disease mucosa: Expression of RANTES, macrophage
inflammatory protein (MIP)-1α, MIP-1β and γ-interferon-inducible
protein-10 by macrophages, lymphocytes, endothelial cells and
granulomas. Inflamm Bowel Dis. 2:88–96. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banks C, Bateman A, Payne R, Johnson P and
Sheron N: Chemokine expression in IBD. Mucosal chemokine expression
is unselectively increased in both ulcerative colitis and Crohn's
disease. J Pathol. 199:28–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katz LH, Kopylov U, Fudim E, et al:
Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's
disease treated with anti-TNF antibodies. Clin Res Hepatol
Gastroenterol. 38:491–498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ueno A, Jijon H, Chan R, et al: Increased
prevalence of circulating novel IL-17 secreting Foxp3 expressing
CD4+ T cells and defective suppressive function of
circulating Foxp3+ regulatory cells support plasticity
between Th17 and regulatory T cells in inflammatory bowel disease
patients. Inflamm Bowel Dis. 19:2522–2534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fitzpatrick LR: Inhibition of IL-17 as a
pharmacological approach for IBD. Int Rev Immunol. 32:544–555.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tillack C, Ehmann LM, Friedrich M, et al:
Anti-TNF antibody-induced psoriasiform skin lesions in patients
with inflammatory bowel disease are characterised by
interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17
cells and respond to anti-IL-12/IL-23 antibody treatment. Gut.
63:567–577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Monteleone I, Sarra M, Pallone F and
Monteleone G: Th17-related cytokines in inflammatory bowel
diseases: friends or foes? Curr Mol Med. 12:592–597. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bianco AM, Girardelli M, Vozzi D, Crovella
S, Kleiner G and Marcuzzi A: Mevalonate kinase deficiency and IBD:
shared genetic background. Gut. 63:1367–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marcuzzi A, Girardelli M, Bianco AM,
Martelossi S, Magnolato A, Tommasini A and Crovella S: Inflammation
profile of four early onset Crohn patients. Gene. 493:282–285.
2012. View Article : Google Scholar : PubMed/NCBI
|
